| Loss of PTEN promotes resistance to T cell–mediated immunotherapy W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... Cancer discovery 6 (2), 202-216, 2016 | 1368 | 2016 |
| Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy T Cascone, JA McKenzie, RM Mbofung, S Punt, Z Wang, C Xu, ... Cell metabolism 27 (5), 977-987. e4, 2018 | 471 | 2018 |
| BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice C Liu, W Peng, C Xu, Y Lou, M Zhang, JA Wargo, JQ Chen, HS Li, ... Clinical cancer research 19 (2), 393-403, 2013 | 400 | 2013 |
| HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes RM Mbofung, JA McKenzie, S Malu, M Zhang, W Peng, C Liu, I Kuiatse, ... Nature communications 8 (1), 451, 2017 | 121 | 2017 |
| The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression L Huang, S Malu, JA McKenzie, MC Andrews, AH Talukder, T Tieu, ... Clinical Cancer Research 24 (14), 3366-3376, 2018 | 87 | 2018 |
| The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy JA McKenzie, RM Mbofung, S Malu, M Zhang, E Ashkin, S Devi, ... JNCI: Journal of the National Cancer Institute 110 (7), 777-786, 2018 | 74 | 2018 |
| Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma W Peng, LJ Williams, C Xu, B Melendez, JA McKenzie, Y Chen, ... Clinical Cancer Research 25 (21), 6406-6416, 2019 | 41 | 2019 |
| Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators J Hou, Y Wang, L Shi, Y Chen, C Xu, A Saeedi, K Pan, R Bohat, NA Egan, ... Journal for immunotherapy of cancer 9 (2), 2021 | 25 | 2021 |
| Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity S Punt, S Malu, JA McKenzie, SZ Manrique, EM Doorduijn, RM Mbofung, ... Cancer Immunology, Immunotherapy 70, 1101-1113, 2021 | 19 | 2021 |
| Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016; 6 (2): 202–16 W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff External Resources Crossref (DOI), 0 | 17 | |
| CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner L Huang, Z Wang, C Liu, C Xu, RM Mbofung, JA McKenzie, H Khong, ... Oncogene 36 (28), 4081-4086, 2017 | 11 | 2017 |
| Weiyi Peng C Liu, L Williams, C Xu, RM Mbofung Abstracts: AACR Virtual Special Conference: Endometrial Cancer: New Biology …, 2020 | 5 | 2020 |
| 117 FT536 path to IND: ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapy J Goulding, B Hancock, R Blum, M Ge, S Gaidarova, P Rogers, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 4 | 2021 |
| Combined genetic ablation of CD54 and CD58 in CAR engineered cytotoxic lymphocytes effectively averts allogeneic immune cell rejection Q Hammer, K Perica, RM Mbofung, H van Ooijen, E Varady, M Jelcic, ... Blood 140 (Supplement 1), 1165-1166, 2022 | 3 | 2022 |
| Alloimmune defense receptor harnesses host immune cell activation to potentiate functional persistence and anti-tumor activity of off-the-shelf, cell-based cancer therapy AM Williams, KL Hayama, Y Pan, B Groff, RM Mbofung, A Chang, C Chen, ... Blood 140 (Supplement 1), 4547-4548, 2022 | 3 | 2022 |
| A novel stealth strategy that activates adoptively transferred allogeneic immune cells and avoids rejection for off-the-shelf cell-based cancer therapy AM Williams, K Hayama, Y Pan, B Groff, RM Mbofung, L Fong, ... Blood 138, 4800, 2021 | 2 | 2021 |
| Genetic ablation of adhesion ligands averts rejection of allogeneic immune cells Q Hammer, K Perica, H van Ooijen, R Mbofung, P Momayyezi, E Varady, ... bioRxiv, 2023.10. 09.557143, 2023 | 1 | 2023 |
| iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma RM Mbofung, X Zong, E Varady, AM Williams, KL Hayama, Y Pan, ... Blood 140 (Supplement 1), 7388-7389, 2022 | 1 | 2022 |
| Off-the-shelf, iPSC-derived CAR-NK cells multiplexed-engineered for the avoidance of allogeneic host immune cell rejection RM Mbofung, AM Williams, K Hayama, Y Pan, B Groff, T Dailey, S Reyes, ... Blood 138, 2795, 2021 | 1 | 2021 |
| Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer P Hwu, JA Mckenzie, RM Mbofung, R Amaria US Patent 10,894,044, 2021 | 1 | 2021 |
